회사소개

MicrobiotiX was established to proactively respond to the rapidly growing crisis of antibiotic resistance as a specialized company focused on the development of bacteriophage-based novel therapeutics.

MicrobiotiX is a leader in phage therapeutics, equipped with the world’s top-tier bacteriophage library, an AI-driven in silico platform, and cGMP-grade phage manufacturing facilities.

To date, the company has secured cumulative investments of approximately KRW 29 billion and has established partnerships with domestic and global pharmaceutical companies as well as renowned research institutes.

MP101, the company’s lead pipeline, is Korea’s first bacteriophage clinical pipeline (First-in-Human). In 2025, the company received approval from the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 clinical trial IND, and in 2026, the first patient was dosed in Korea (First-Patient-In).

Antimicrobial agents are drugs that have saved countless lives since their discovery, but their development and pharmaceutical process is very slow and arduous. Microorganisms are gaining resistance to these antimicrobial agents. This undermines all of the hard work put into their development. This is due to the extreme diversity and genetic flexibility of these microorganisms. This problem is only expected to worsen in the future for 2 reasons: antimicrobial candidates are dwindling, and even with large investments, the new antimicrobial mechanism will be countered with just a few generations of mutations. Therefore, there is an urgent need to supplement or replace the existing antibacterial treatment framework. The countermeasures we must take are clear. Recently, the NIH in the United States proposed a shift to explore alternative therapies to overcome antimicrobial resistance, including bacteriophage therapy and synthetic microbiota. Yonsei University’s diagnostic laboratory, the academic foundation of MicrobiotiX, and the Institute of Bacterial Resistance have conducted a world-class antimicrobial resistance study. During this research, many world-first discoveries were made. The research team then explored innovative ways to overcome antimicrobial resistance and from this discussion MicrobiotiX was founded. The specific method that MicrobiotiX is currently pursuing is through bacteriophage therapy. Through bacteriophages, we want to reset the relationship between humans and antimicrobial resistant bacteria. Through, both Korean and American research teams, we are investigating phages to be used in preclinical and clinical trials. I’ll continue to work hard to push our research forward and I look forward to your support.

Dongeun Yong, CEO

MicrobiotiX was established to proactively respond to the rapidly growing crisis of antibiotic resistance as a specialized company focused on the development of bacteriophage-based novel therapeutics.

MicrobiotiX is a leader in phage therapeutics, equipped with the world’s top-tier bacteriophage library, an AI-driven in silico platform, and cGMP-grade phage manufacturing facilities.

To date, the company has secured cumulative investments of approximately KRW 29 billion and has established partnerships with domestic and global pharmaceutical companies as well as renowned research institutes.

MP101, the company’s lead pipeline, is Korea’s first bacteriophage clinical pipeline (First-in-Human). In 2025, the company received approval from the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 clinical trial IND, and in 2026, the first patient was dosed in Korea (First-Patient-In).

Antimicrobial agents are drugs that have saved countless lives since their discovery, but their development and pharmaceutical process is very slow and arduous. Microorganisms are gaining resistance to these antimicrobial agents. This undermines all of the hard work put into their development. This is due to the extreme diversity and genetic flexibility of these microorganisms. This problem is only expected to worsen in the future for 2 reasons: antimicrobial candidates are dwindling, and even with large investments, the new antimicrobial mechanism will be countered with just a few generations of mutations. Therefore, there is an urgent need to supplement or replace the existing antibacterial treatment framework. The countermeasures we must take are clear. Recently, the NIH in the United States proposed a shift to explore alternative therapies to overcome antimicrobial resistance, including bacteriophage therapy and synthetic microbiota. Yonsei University’s diagnostic laboratory, the academic foundation of MicrobiotiX, and the Institute of Bacterial Resistance have conducted a world-class antimicrobial resistance study. During this research, many world-first discoveries were made. The research team then explored innovative ways to overcome antimicrobial resistance and from this discussion MicrobiotiX was founded. The specific method that MicrobiotiX is currently pursuing is through bacteriophage therapy. Through bacteriophages, we want to reset the relationship between humans and antimicrobial resistant bacteria. Through, both Korean and American research teams, we are investigating phages to be used in preclinical and clinical trials. I’ll continue to work hard to push our research forward and I look forward to your support.

Dongeun Yong, CEO

Privacy Policy Prohibition of Unauthorized Email Collection


Possesses a target library for multidrug-resistant bacteria	Received approval for free pre-clinical serivce by the US institution	A cumulative institutional investment of 29 billion KRW


First-in-Human Clinical Trial of Korea’s First Bacteriophage Therapy	Joint research with LigaChem Biosciences	Establishment of a cGMP-class facility (CDMO service)